Tumor-homing Bispecific Antibodies that Co-engage EPHA2 and Frizzled Receptors Target RNF43-mutant Pancreatic Cancer and Minimize Toxicity
Disease and Therapeutics · 2026-11 · 100027
DOI: 10.1016/j.dist.2026.100027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease and Therapeutics, 2026-11. Verfasst von Jarrett J. Adams und 17 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Many cancers utilize aberrant β-catenin signaling to drive tumor growth. Tumors harboring mutations in RNF43 fail to appropriately regulate Fzd receptor expression on the cell surface, leading to dysfunctional activation of β-catenin in response to Wnt ligands. We previously developed an inhibitory pan-Fzd antibody that targets six Fzd receptors and potently inhibits β-catenin-dependent signaling and tumor progression in vivo . Though effective, this antibody treatment was intolerable in mice at high doses, due to on-target toxicity in tissues maintained by adult stem niches. We hypothesized that selective targeting of tumor cells may improve the safety profile of pan-Fzd antibodies. EPHA2 is a common tumor marker that is highly expressed in pancreatic cancer and correlates with invasive disease. We engineered a bispecific IgG (bsIgG) to simultaneously target EPHA2 and inhibit six Fzd homologues, and we evaluated its safety profile. Treatment with the bsIgG was better tolerated in healthy mice compared to treatment with IgGs targeting only Fzds. Mice engrafted with RNF43 -mutant HPAF-II xenografts responded well to the bsIgG treatment yet showed no signs of gross toxicity even at high dose (40 mg/kg). Biodistribution analysis of the bsIgG showed significant reductions in exposure for liver, bone and gastrointestinal tract where toxicity from Fzd inhibition commonly presents. These data suggest that the bsIgG preferentially targets tumors that co-express EPHA2 and Fzd, which minimizes exposure to Fzd inhibition in healthy tissues and provides a safe means for targeting Fzd oncogenic signaling in cancer.
Förderung
- Natural Sciences and Engineering Research Council of Canada
- Canadian Institutes of Health Research
Zitieren
APA
Adams, J. J., Kim, Y. H., Barreto, K., Bernhard, W., Muzalevska, K., Salguero, A. M., Hokanson, C. A., Castano, V., Liang, R., Jarvik, N., Chen, C., Gorelik, M., Ploder, L., Garcia, J., Pot, I., Geyer, C. R., Angers, S., & Sidhu, S. S. (2026). Tumor-homing Bispecific Antibodies that Co-engage EPHA2 and Frizzled Receptors Target RNF43-mutant Pancreatic Cancer and Minimize Toxicity. Disease and Therapeutics, 100027. https://doi.org/10.1016/j.dist.2026.100027
Vancouver
Adams JJ, Kim YH, Barreto K, Bernhard W, Muzalevska K, Salguero AM, et al. Tumor-homing Bispecific Antibodies that Co-engage EPHA2 and Frizzled Receptors Target RNF43-mutant Pancreatic Cancer and Minimize Toxicity. Disease and Therapeutics. 2026:100027. doi:10.1016/j.dist.2026.100027
BibTeX
@article{Adams2026,
author = {Adams, Jarrett J. and Kim, Yun Hye and Barreto, Kris and Bernhard, Wendy and Muzalevska, Kate and Salguero, Andres Medina and Hokanson, Craig A. and Castano, Valeria and Liang, Ryan and Jarvik, Nick and Chen, Chao and Gorelik, Maryna and Ploder, Lynda and Garcia, Julia and Pot, Isabelle and Geyer, C. Ronald and Angers, Stephane and Sidhu, Sachdev S.},
title = {Tumor-homing Bispecific Antibodies that Co-engage EPHA2 and Frizzled Receptors Target RNF43-mutant Pancreatic Cancer and Minimize Toxicity},
journal = {Disease and Therapeutics},
year = {2026},
pages = {100027},
doi = {10.1016/j.dist.2026.100027}
}
EUVIMED